Transient Increase of Interferon-Stimulated Genes and No Clinical Benefit by Chloroquine Treatment During Acute Simian Immunodeficiency Virus Infection of Macaques
Restricted accessResearch articleFirst published online April, 2014
Transient Increase of Interferon-Stimulated Genes and No Clinical Benefit by Chloroquine Treatment During Acute Simian Immunodeficiency Virus Infection of Macaques
Simian immunodeficiency virus (SIV) infection leads to AIDS in experimentally infected Rhesus macaques similarly to HIV-infected humans. In contrast, SIV infection of natural hosts is characterized by a down-regulation of innate acute responses to the virus within a few weeks of infection and results in limited pathology. Chloroquine (CQ) has been used in the treatment or prevention of malaria and has recently been shown to cause a decrease of immune activation and CD4 cell loss in HIV-infected individuals treated with antiretroviral therapy. Here, we treated Rhesus macaques with CQ during the acute phase of SIVmac251 infection with the intent to decrease viral-induced immune activation and possibly limit disease progression. Contrary to what was expected, CQ treatment resulted in a temporary increased expression of interferon (IFN)-stimulating genes and it worsened the recovery of CD4+ T cells in the blood. Our findings confirm recent results observed in asymptomatic HIV-infected patients and suggest that CQ does not provide an obvious benefit in the absence of antiretroviral therapy.
Get full access to this article
View all access options for this article.
References
1.
ValdezH and LedermanMM: Cytokines and cytokine therapies in HIV infection. AIDS Clin Rev, 1997;1997–1998:187–228.
2.
ConnollyNC, RiddlerSA, and RinaldoCR: Proinflammatory cytokines in HIV disease–a review and rationale for new therapeutic approaches. AIDS Rev, 2005; 7(3):168–180.
3.
BoassoA and ShearerGM: Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin Immunol, 2008; 126(3):235–242.
4.
AscherMS, SheppardHW, KrowkaJF, and BremermannHJ: AIDS as immune system activation. Key questions that remain. Adv Exp Med Biol, 1995; 374:203–210.
5.
SodoraDL and SilvestriG: Immune activation and AIDS pathogenesis. AIDS, 2008; 22(4):439–446.
6.
DouekD: HIV disease progression: Immune activation, microbes, and a leaky gut. Top HIV Med, 2007; 15(4):114–117.
7.
HerbeuvalJP, NilssonJ, BoassoA, et al.: Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients. Proc Natl Acad Sci USA, 2006; 103(18):7000–7005.
8.
AccorneroP, RadrizzaniM, DeliaD, et al.: Differential susceptibility to HIV-GP120-sensitized apoptosis in CD4+ T-cell clones with different T-helper phenotypes: Role of CD95/CD95L interactions. Blood, 1997; 89(2):558–569.
9.
BoassoA, HardyAW, AndersonSA, DolanMJ, and ShearerGM: HIV-induced type I interferon and tryptophan catabolism drive T cell dysfunction despite phenotypic activation. PLoS One, 2008; 3(8):e2961.
10.
HerbeuvalJP and ShearerGM: HIV-1 immunopathogenesis: How good interferon turns bad. Clin Immunol, 2007; 123(2):121–128.
11.
BoassoA, VaccariM, FuchsD, et al.: Combined effect of antiretroviral therapy and blockade of IDO in SIV-infected rhesus macaques. J Immunol, 2009; 182(7):4313–4320.
12.
PithaPM: Multiple effects of interferon on the replication of human immunodeficiency virus type 1. Antiviral Res, 1994; 24(2–3):205–219.
13.
FoxNW and McArthurCP: Acquired immunodeficiency syndrome—a review and update. History, characteristics of human immunodeficiency virus infection, its replication, biologic factors, and pathogenicity. Arch Fam Med, 1993; 2(10):1068–1077.
14.
WallaceDJ: The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: A critical review. Lupus, 1996; 5(Suppl 1):S59–S64.
15.
KlingerG, MoradY, WestallCA, et al.: Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet, 2001; 358(9284):813–814.
16.
TsaiWP, NaraPL, KungHF, and OroszlanS: Inhibition of human immunodeficiency virus infectivity by chloroquine. AIDS Res Hum Retroviruses, 1990; 6(4):481–489.
17.
SperberK, KalbTH, StecherVJ, BanerjeeR, and MayerL: Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes. AIDS Res Hum Retroviruses, 1993; 9(1):91–98.
18.
SavarinoA, LuciaMB, RastrelliE, et al.: Anti-HIV effects of chloroquine: Inhibition of viral particle glycosylation and synergism with protease inhibitors. J Acquir Immune Defic Syndr, 2004; 35(3):223–232.
19.
BeignonAS, McKennaK, SkoberneM, et al.: Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest, 2005; 115(11):3265–3275.
20.
SchmidtB, AshlockBM, FosterH, FujimuraSH, and LevyJA: HIV-infected cells are major inducers of plasmacytoid dendritic cell interferon production, maturation, and migration. Virology, 2005; 343(2):256–266.
21.
HardyAW, GrahamDR, ShearerGM, and HerbeuvalJP: HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN-alpha. Proc Natl Acad Sci USA, 2007; 104(44):17453–17458.
22.
MaM, WangL, YangJ, et al.: Age-related impaired Th1 responses to PRV vaccine in vivo in aged pigs. Mol Immunol, 2012; 52(3–4):217–223.
23.
RutzM, MetzgerJ, GellertT, et al.: Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol, 2004; 34(9):2541–2550.
24.
PiconiS, ParisottoS, RizzardiniG, et al.: Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood, 2011; 118(12):3263–3272.
25.
MurraySM, DownCM, BoulwareDR, et al.: Reduction of immune activation with chloroquine therapy during chronic HIV infection. J Virol, 2010; 84(22):12082–12086.
26.
PatonNI, GoodallRL, DunnDT, et al.: Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: A randomized controlled trial. JAMA, 2012; 308(4):353–361.
27.
LiovatAS, JacquelinB, PloquinMJ, Barre-SinoussiF, and Muller-TrutwinMC: African non human primates infected by SIV—why don't they get sick? Lessons from studies on the early phase of non-pathogenic SIV infection. Curr HIV Res, 2009; 7(1):39–50.
28.
PaiardiniM, PandreaI, ApetreiC, and SilvestriG: Lessons learned from the natural hosts of HIV-related viruses. Annu Rev Med, 2009; 60:485–495.
29.
MandlJN, BarryAP, VanderfordTH, et al.: Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med, 2008; 14(10):1077–1087.
30.
JacquelinB, MayauV, TargatB, et al.: Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest, 2009; 119(12):3544–3555.
31.
BosingerSE, LiQ, GordonSN, et al.: Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J Clin Invest, 2009; 119(12):3556–3572.
32.
BlessbornD, NeaminG, BergqvistY, and LindegardhN: A new approach to evaluate stability of amodiaquine and its metabolite in blood and plasma. J Pharm Biomed Anal, 2006; 41(1):207–212.
33.
RomanoJW, ShurtliffRN, DobratzE, et al.: Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology. J Virol Methods, 2000; 86(1):61–70.
34.
VaccariM, BoassoA, MaZM, et al.: CD4+ T-cell loss and delayed expression of modulators of immune responses at mucosal sites of vaccinated macaques following SIV(mac251) infection. Mucosal Immunol, 2008; 1(6):497–507.
35.
VaccariM, TrindadeCJ, VenzonD, ZanettiM, and FranchiniG: Vaccine-Induced CD8+ central memory T cells in protection from simian AIDS. J Immunol, 2005; 175(6):3502–3507.
36.
BoassoA, HerbeuvalJP, HardyAW, WinklerC, and ShearerGM: Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells. Blood, 2005; 105(4):1574–1581.
37.
HughesR, TowersG, and NoursadeghiM: Innate immune interferon responses to human immunodeficiency virus-1 infection. Rev Med Virol, 2012; 22(4):257–266.
38.
MillerDR, KhalilSK, and NygardGA: Steady-state pharmacokinetics of hydroxychloroquine in rheumatoid arthritis patients. DICP, 1991; 25(12):1302–1305.
39.
RosenthalAR, KolbH, BergsmaD, HuxsollD, and HopkinsJL: Chloroquine retinopathy in the rhesus monkey. Invest Ophthalmol Vis Sci, 1978; 17(12):1158–1175.
NaardingMA, BaanE, PollakisG, and PaxtonWA: Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4+ T-lymphocytes. Retrovirology, 2007; 4:6.
42.
SilvestriG, SodoraDL, KoupRA, et al.: Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity, 2003; 18(3):441–452.
43.
BrenchleyJM, PriceDA, SchackerTW, et al.: Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med, 2006; 12(12):1365–1371.
44.
FunderburgN, LucianoAA, JiangW, et al.: Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis. PLoS One, 2008; 3(4):e1915.
45.
BenvenisteO, FlahaultA, RollotF, et al.: Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. J Infect Dis, 2005; 191(10):1670–1679.
46.
FoxRI: Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum, 1993; 23(2 Suppl 1):82–91.
47.
WallaceDJ: Antimalarial agents and lupus. Rheum Dis Clin North Am, 1994; 20(1):243–263.
48.
MacfarlaneDE and ManzelL: Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. J Immunol, 1998; 160(3):1122–1131.
49.
ManzelL, StrekowskiL, IsmailFM, SmithJC, and MacfarlaneDE: Antagonism of immunostimulatory CpG-oligodeoxynucleotides by 4-aminoquinolines and other weak bases: Mechanistic studies. J Pharmacol Exp Ther, 1999; 291(3):1337–1347.
50.
WeberF, KochsG, and HallerO: Inverse interference: How viruses fight the interferon system. Viral Immunol, 2004; 17(4):498–515.
51.
HongZ, JiangZ, LiangxiW, et al.: Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release. Int Immunopharmacol, 2004; 4(2):223–234.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
